Login Register Cart 0
Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Molecular Dynamics Simulations of HDAC-ligand Complexes Towards the Design of New Anticancer Compounds

Author(s): Varun Dewaker and Yenamandra S. Prabhakar*

Volume 23, Issue 29, 2023

Published on: 28 September, 2023

Page: [2743 - 2764] Pages: 22

DOI: 10.2174/0115680266250924230920042845

Price: $65

conference banner
Abstract

Quantitative Structure-activity Relationship (QSAR) studies gained a foothold in the mid-1960s to rationalise the biological activity of medicinally important compounds. Since then, the advancements in computer hardware and software added many new techniques and areas to this field of study. Molecular dynamics (MD) simulations are one such technique in direct drug design approaches. MD simulations have a special place in drug design studies because they decode the dynamics of intermolecular interactions between a biological target and its potential ligands/inhibitors. The trajectories from MD simulations provide different non-bonding interaction parameters to assess the compatibility of the protein-ligand complex and thereby facilitate the design of prospective compounds prior to their wet-lab exploration. Histone deacetylases (HDACs) play a key role in epigenetics and they are promising drug targets for cancer and various other diseases. This review attempts to shed some light on the modelling studies of HDAC inhibitors as anticancer agents. In view of the advantages of MD simulations in direct drug design, this review also discusses the fragment-based approach in designing new inhibitors of HDAC8 and HDAC2, starting from the interaction energies of ligand fragments obtained from the MD simulations of respective protein-ligand complexes. Here, the design of new anticancer compounds from largazole thiol, trichostatin A, vorinostat, and several other prototype compounds are reviewed. These studies may stimulate the interest of medicinal chemists in MD simulations as a direct drug design approach for new drug development.

« Previous Next »
Graphical Abstract

[1]
Cherkasov, A.; Muratov, E.N.; Fourches, D.; Varnek, A.; Baskin, I.I.; Cronin, M.; Dearden, J.; Gramatica, P.; Martin, Y.C.; Todeschini, R.; Consonni, V.; Kuz’min, V.E.; Cramer, R.; Benigni, R.; Yang, C.; Rathman, J.; Terfloth, L.; Gasteiger, J.; Richard, A.; Tropsha, A. QSAR modeling: Where have you been? Where are you going to? J. Med. Chem., 2014, 57(12), 4977-5010.
[http://dx.doi.org/10.1021/jm4004285] [PMID: 24351051]
[2]
Muratov, E.N.; Bajorath, J.; Sheridan, R.P.; Tetko, I.V.; Filimonov, D.; Poroikov, V.; Oprea, T.I.; Baskin, I.I.; Varnek, A.; Roitberg, A.; Isayev, O.; Curtalolo, S.; Fourches, D.; Cohen, Y.; Aspuru-Guzik, A.; Winkler, D.A.; Agrafiotis, D.; Cherkasov, A.; Tropsha, A. QSAR without borders. Chem. Soc. Rev., 2020, 49(11), 3525-3564.
[http://dx.doi.org/10.1039/D0CS00098A] [PMID: 32356548]
[3]
Hansch, C. Quantitative approach to biochemical Structure-activity relationships. Acc. Chem. Res., 1969, 2(8), 232-239.
[http://dx.doi.org/10.1021/ar50020a002]
[4]
Selassie, C.; Verma, R.P. History of Quantitative Structure–Activity Relationships.Burger’s Medicinal Chemistry and Drug Discovery; Wiley, 2010, pp. 1-96.
[http://dx.doi.org/10.1002/0471266949.bmc001.pub2]
[5]
Martin, Y.C. Hansch analysis 50 years on. Wiley Interdiscip. Rev. Comput. Mol. Sci., 2012, 2(3), 435-442.
[http://dx.doi.org/10.1002/wcms.1096]
[6]
Roy, K.; Kar, S.; Das, R.N. Introduction to 3D-QSAR. Underst. Basics QSAR Appl. Pharm. Sci. Risk Assess., 2015, 291-317.
[7]
Verma, J.; Khedkar, V.; Coutinho, E. 3D-QSAR in drug design-a review. Curr. Top. Med. Chem., 2010, 10(1), 95-115.
[http://dx.doi.org/10.2174/156802610790232260] [PMID: 19929826]
[8]
Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110(18), 5959-5967.
[http://dx.doi.org/10.1021/ja00226a005] [PMID: 22148765]
[9]
Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem., 1994, 37(24), 4130-4146.
[http://dx.doi.org/10.1021/jm00050a010] [PMID: 7990113]
[10]
Verma, S.; Prabhakar, Y. Target based drug design-a reality in virtual sphere. Curr. Med. Chem., 2015, 22(13), 1603-1630.
[http://dx.doi.org/10.2174/0929867322666150209151209] [PMID: 25666805]
[11]
Scheiner, S. Understanding noncovalent bonds and their controlling forces. J. Chem. Phys., 2020, 153(14), 140901.
[http://dx.doi.org/10.1063/5.0026168] [PMID: 33086824]
[12]
Zhou, H.X.; Pang, X. Electrostatic interactions in protein structure, folding, binding, and condensation. Chem. Rev., 2018, 118(4), 1691-1741.
[http://dx.doi.org/10.1021/acs.chemrev.7b00305] [PMID: 29319301]
[13]
Johnson, E.R.; Keinan, S.; Mori-Sánchez, P.; Contreras-García, J.; Cohen, A.J.; Yang, W. Revealing noncovalent interactions. J. Am. Chem. Soc., 2010, 132(18), 6498-6506.
[http://dx.doi.org/10.1021/ja100936w] [PMID: 20394428]
[14]
Garbett, N.C.; Chaires, J.B. Thermodynamic studies for drug design and screening. Expert Opin. Drug Discov., 2012, 7(4), 299-314.
[http://dx.doi.org/10.1517/17460441.2012.666235] [PMID: 22458502]
[15]
Decherchi, S.; Cavalli, A. Thermodynamics and kinetics of drug-target binding by molecular simulation. Chem. Rev., 2020, 120(23), 12788-12833.
[http://dx.doi.org/10.1021/acs.chemrev.0c00534] [PMID: 33006893]
[16]
Pinzi, L.; Rastelli, G. Molecular Docking: Shifting Paradigms in Drug Discovery. Int. J. Mol. Sci., 2019, 20(18), 4331.
[http://dx.doi.org/10.3390/ijms20184331] [PMID: 31487867]
[17]
Kitchen, D.B.; Decornez, H.; Furr, J.R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat. Rev. Drug Discov., 2004, 3(11), 935-949.
[http://dx.doi.org/10.1038/nrd1549] [PMID: 15520816]
[18]
Torres, P.H.M.; Sodero, A.C.R.; Jofily, P.; Silva-Jr, F.P. Key topics in molecular docking for drug design. Int. J. Mol. Sci., 2019, 20(18), 4574.
[http://dx.doi.org/10.3390/ijms20184574] [PMID: 31540192]
[19]
Skjærven, L.; Reuter, N.; Martinez, A. Dynamics, flexibility and ligand-induced conformational changes in biological macromolecules: A computational approach. Future Med. Chem., 2011, 3(16), 2079-2100.
[http://dx.doi.org/10.4155/fmc.11.159] [PMID: 22098354]
[20]
Durrant, J.D.; McCammon, J.A. Molecular dynamics simulations and drug discovery. BMC Biol., 2011, 9(1), 71.
[http://dx.doi.org/10.1186/1741-7007-9-71] [PMID: 22035460]
[21]
Maveyraud, L.; Mourey, L. Protein X-ray crystallography and drug discovery. Molecules, 2020, 25(5), 1030.
[http://dx.doi.org/10.3390/molecules25051030] [PMID: 32106588]
[22]
Cavasotto, C.N.; Phatak, S.S. Homology modeling in drug discovery: Current trends and applications. Drug Discov. Today, 2009, 14(13-14), 676-683.
[http://dx.doi.org/10.1016/j.drudis.2009.04.006] [PMID: 19422931]
[23]
Cornell, W.D.; Cieplak, P.; Bayly, C.I.; Gould, I.R.; Merz, K.M.; Ferguson, D.M.; Spellmeyer, D.C.; Fox, T.; Caldwell, J.W.; Kollman, P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc., 1995, 117(19), 5179-5197.
[http://dx.doi.org/10.1021/ja00124a002]
[24]
Weiner, P.K.; Kollman, P.A. AMBER: Assisted model building with energy refinement. A general program for modeling molecules and their interactions. J. Comput. Chem., 1981, 2(3), 287-303.
[http://dx.doi.org/10.1002/jcc.540020311]
[25]
Brooks, B.R.; Brooks, C.L., III; Mackerell, A.D., Jr; Nilsson, L.; Petrella, R.J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A.R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R.W.; Post, C.B.; Pu, J.Z.; Schaefer, M.; Tidor, B.; Venable, R.M.; Woodcock, H.L.; Wu, X.; Yang, W.; York, D.M.; Karplus, M. CHARMM: The biomolecular simulation program. J. Comput. Chem., 2009, 30(10), 1545-1614.
[http://dx.doi.org/10.1002/jcc.21287] [PMID: 19444816]
[26]
MacKerell, A.D., Jr; Bashford, D.; Bellott, M.; Dunbrack, R.L., Jr; Evanseck, J.D.; Field, M.J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F.T.K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D.T.; Prodhom, B.; Reiher, W.E.; Roux, B.; Schlenkrich, M.; Smith, J.C.; Stote, R.; Straub, J.; Watanabe, M.; Wiórkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B, 1998, 102(18), 3586-3616.
[http://dx.doi.org/10.1021/jp973084f] [PMID: 24889800]
[27]
Lifson, S.; Warshel, A. Consistent Force field for calculations of conformations, vibrational spectra, and enthalpies of cycloalkane and n -Alkane molecules. J. Chem. Phys., 1968, 49(11), 5116-5129.
[http://dx.doi.org/10.1063/1.1670007]
[28]
Dauber-Osguthorpe, P.; Roberts, V.A.; Osguthorpe, D.J.; Wolff, J.; Genest, M.; Hagler, A.T. Structure and energetics of ligand binding to proteins:Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins, 1988, 4(1), 31-47.
[http://dx.doi.org/10.1002/prot.340040106] [PMID: 3054871]
[29]
Gaedt, K.; Holtje, H-D. Consistent Valence force-field parameterization of bond lengths and angles with quantum chemicalab initio methods applied to some heterocyclic dopamine d3-receptor agonists. J. Comput. Chem., 1998, 19, 935-946.
[http://dx.doi.org/10.1002/(SICI)1096-987X(199806)19:8<935::AID-JCC12>3.0.CO;2-6]
[30]
Phillips, J.C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R.D.; Kalé, L.; Schulten, K. Scalable molecular dynamics with NAMD. J. Comput. Chem., 2005, 26(16), 1781-1802.
[http://dx.doi.org/10.1002/jcc.20289] [PMID: 16222654]
[31]
Berendsen, H.J.C.; van der Spoel, D.; van Drunen, R. GROMACS: A message-passing parallel molecular dynamics implementation. Comput. Phys. Commun., 1995, 91(1-3), 43-56.
[http://dx.doi.org/10.1016/0010-4655(95)00042-E]
[32]
Case, D.A.; Cheatham, T.E., III; Darden, T.; Gohlke, H.; Luo, R.; Merz, K.M., Jr; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R.J. The Amber biomolecular simulation programs. J. Comput. Chem., 2005, 26(16), 1668-1688.
[http://dx.doi.org/10.1002/jcc.20290] [PMID: 16200636]
[33]
Kirkwood, J.G. Statistical mechanics of fluid mixtures. J. Chem. Phys., 1935, 3(5), 300-313.
[http://dx.doi.org/10.1063/1.1749657]
[34]
Zwanzig, R.W.; Kirkwood, J.G.; Oppenheim, I.; Alder, B.J. Statistical mechanical theory of transport processes. VII. The coefficient of thermal conductivity of monatomic liquids. J. Chem. Phys., 1954, 22(5), 783-790.
[http://dx.doi.org/10.1063/1.1740193]
[35]
Bowers, K.J.; Chow, D.E.; Xu, H.; Dror, R.O.; Eastwood, M.P.; Gregersen, B.A.; Klepeis, J.L.; Kolossvary, I.; Moraes, M.A.; Sacerdoti, F.D.; Salmon, J.K.; Shan, Y.; Shaw, D.E. Scalable algorithms for molecular dynamics simulations on commodity clusters. In: Institute of Electrical and Electronics Engineers (IEEE); , 2007; pp. 43-43.
[36]
Kollman, P. Free energy calculations: Applications to chemical and biochemical phenomena. Chem. Rev., 1993, 93(7), 2395-2417.
[http://dx.doi.org/10.1021/cr00023a004]
[37]
Jorgensen, W.L.; Thomas, L.L. Perspective on free-energy perturbation calculations for chemical equilibria. J. Chem. Theory Comput., 2008, 4(6), 869-876.
[http://dx.doi.org/10.1021/ct800011m] [PMID: 19936324]
[38]
Zacharias, M.; Straatsma, T.P.; McCammon, J.A. Separation-shifted scaling, a new scaling method for Lennard-Jones interactions in thermodynamic integration. J. Chem. Phys., 1994, 100(12), 9025-9031.
[http://dx.doi.org/10.1063/1.466707]
[39]
Beveridge, D.L.; DiCapua, F.M. Free energy via molecular simulation: Applications to chemical and biomolecular systems. Annu. Rev. Biophys. Biophys. Chem., 1989, 18(1), 431-492.
[http://dx.doi.org/10.1146/annurev.bb.18.060189.002243] [PMID: 2660832]
[40]
Genheden, S.; Ryde, U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov., 2015, 10(5), 449-461.
[http://dx.doi.org/10.1517/17460441.2015.1032936] [PMID: 25835573]
[41]
Miller, B.R., III; McGee, T.D., Jr; Swails, J.M.; Homeyer, N.; Gohlke, H.; Roitberg, A.E. MMPBSA.py : An efficient program for end-state free energy calculations. J. Chem. Theory Comput., 2012, 8(9), 3314-3321.
[http://dx.doi.org/10.1021/ct300418h] [PMID: 26605738]
[42]
Chen, J.; Wang, X.; Zhu, T.; Zhang, Q.; Zhang, J.Z.H. A Comparative Insight into Amprenavir Resistance of Mutations V32I, G48V, I50V, I54V, and I84V in HIV-1 Protease Based on Thermodynamic Integration and MM-PBSA Methods. J. Chem. Inf. Model., 2015, 55(9), 1903-1913.
[http://dx.doi.org/10.1021/acs.jcim.5b00173] [PMID: 26317593]
[43]
Chen, J.; Zeng, Q.; Wang, W.; Sun, H.; Hu, G. Decoding the Identification Mechanism of an SAM-III Riboswitch on Ligands through Multiple Independent Gaussian-Accelerated Molecular Dynamics Simulations. J. Chem. Inf. Model., 2022, 62(23), 6118-6132.
[http://dx.doi.org/10.1021/acs.jcim.2c00961] [PMID: 36440874]
[44]
Pan, Y.; Gao, D.; Zhan, C.G. Modeling the catalysis of anti-cocaine catalytic antibody: Competing reaction pathways and free energy barriers. J. Am. Chem. Soc., 2008, 130(15), 5140-5149.
[http://dx.doi.org/10.1021/ja077972s] [PMID: 18341277]
[45]
Hao, G.F.; Wang, F.; Li, H.; Zhu, X.L.; Yang, W.C.; Huang, L.S.; Wu, J.W.; Berry, E.A.; Yang, G.F. Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex. J. Am. Chem. Soc., 2012, 134(27), 11168-11176.
[http://dx.doi.org/10.1021/ja3001908] [PMID: 22690928]
[46]
Duan, L.; Liu, X.; Zhang, J.Z.H. Interaction entropy: A new paradigm for highly efficient and reliable computation of protein–ligand binding free energy. J. Am. Chem. Soc., 2016, 138(17), 5722-5728.
[http://dx.doi.org/10.1021/jacs.6b02682] [PMID: 27058988]
[47]
Ollitrault, P.J.; Miessen, A.; Tavernelli, I. Molecular Quantum Dynamics: A quantum computing perspective. Acc. Chem. Res., 2021, 54(23), 4229-4238.
[http://dx.doi.org/10.1021/acs.accounts.1c00514] [PMID: 34787398]
[48]
Mortier, J.; Rakers, C.; Bermudez, M.; Murgueitio, M.S.; Riniker, S.; Wolber, G. The impact of molecular dynamics on drug design: Applications for the characterization of ligand–macromolecule complexes. Drug Discov. Today, 2015, 20(6), 686-702.
[http://dx.doi.org/10.1016/j.drudis.2015.01.003] [PMID: 25615716]
[49]
Arrowsmith, C.H.; Bountra, C.; Fish, P.V.; Lee, K.; Schapira, M. Epigenetic protein families: A new frontier for drug discovery. Nat. Rev. Drug Discov., 2012, 11(5), 384-400.
[http://dx.doi.org/10.1038/nrd3674] [PMID: 22498752]
[50]
López, J.E.; Sullivan, E.D.; Fierke, C.A. Metal-dependent Deacetylases: Cancer and Epigenetic Regulators. ACS Chem. Biol., 2016, 11(3), 706-716.
[http://dx.doi.org/10.1021/acschembio.5b01067] [PMID: 26907466]
[51]
Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis, 2010, 31(1), 27-36.
[http://dx.doi.org/10.1093/carcin/bgp220] [PMID: 19752007]
[52]
Ptak, C.; Petronis, A. Epigenetics and complex disease: From etiology to new therapeutics. Annu. Rev. Pharmacol. Toxicol., 2008, 48(1), 257-276.
[http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094731] [PMID: 17883328]
[53]
Darwiche, N. Epigenetic mechanisms and the hallmarks of cancer: An intimate affair. Am. J. Cancer Res., 2020, 10(7), 1954-1978.
[PMID: 32774995]
[54]
New, M.; Olzscha, H.; La Thangue, N.B. HDAC inhibitor-based therapies: Can we interpret the code? Mol. Oncol., 2012, 6(6), 637-656.
[http://dx.doi.org/10.1016/j.molonc.2012.09.003] [PMID: 23141799]
[55]
Bieliauskas, A.V.; Pflum, M.K.H. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev., 2008, 37(7), 1402-1413.
[http://dx.doi.org/10.1039/b703830p] [PMID: 18568166]
[56]
Lane, A.A.; Chabner, B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol., 2009, 27(32), 5459-5468.
[http://dx.doi.org/10.1200/JCO.2009.22.1291] [PMID: 19826124]
[57]
Deschamps, N.; Simões-Pires, C.A.; Carrupt, P.A.; Nurisso, A. How the flexibility of human histone deacetylases influences ligand binding: An overview. Drug Discov. Today, 2015, 20(6), 736-742.
[http://dx.doi.org/10.1016/j.drudis.2015.01.004] [PMID: 25597521]
[58]
Manal, M.; Chandrasekar, M.J.N.; Gomathi Priya, J.; Nanjan, M.J. Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorg. Chem., 2016, 67, 18-42.
[http://dx.doi.org/10.1016/j.bioorg.2016.05.005] [PMID: 27239721]
[59]
Corminboeuf, C.; Hu, P.; Tuckerman, M.E.; Zhang, Y. Unexpected deacetylation mechanism suggested by a density functional theory QM/MM study of histone-deacetylase-like protein. J. Am. Chem. Soc., 2006, 128(14), 4530-4531.
[http://dx.doi.org/10.1021/ja0600882] [PMID: 16594663]
[60]
Wu, R.; Wang, S.; Zhou, N.; Cao, Z.; Zhang, Y. A proton-shuttle reaction mechanism for histone deacetylase 8 and the catalytic role of metal ions. J. Am. Chem. Soc., 2010, 132(27), 9471-9479.
[http://dx.doi.org/10.1021/ja103932d] [PMID: 20568751]
[61]
Estiu, G.; West, N.; Mazitschek, R.; Greenberg, E.; Bradner, J.E.; Wiest, O. On the inhibition of histone deacetylase 8. Bioorg. Med. Chem., 2010, 18(11), 4103-4110.
[http://dx.doi.org/10.1016/j.bmc.2010.03.080] [PMID: 20472442]
[62]
Kashyap, K.; Kakkar, R. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies. J. Biomol. Struct. Dyn., 2020, 38(1), 48-65.
[http://dx.doi.org/10.1080/07391102.2019.1567388] [PMID: 30633630]
[63]
Zhou, H.; Wang, C.; Deng, T.; Tao, R.; Li, W. Novel urushiol derivatives as HDAC8 inhibitors: Rational design, virtual screening, molecular docking and molecular dynamics studies. J. Biomol. Struct. Dyn., 2018, 36(8), 1966-1978.
[http://dx.doi.org/10.1080/07391102.2017.1344568] [PMID: 28632421]
[64]
Uba, A.I.; Yelekçi, K. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: A combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay. J. Biomol. Struct. Dyn., 2018, 36(12), 3231-3245.
[http://dx.doi.org/10.1080/07391102.2017.1384402] [PMID: 28938863]
[65]
Sixto-López, Y.; Bello, M.; Correa-Basurto, J. Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6. J. Biomol. Struct. Dyn., 2019, 37(18), 4701-4720.
[http://dx.doi.org/10.1080/07391102.2018.1557560] [PMID: 30558483]
[66]
Sixto-López, Y.; Bello, M.; Correa-Basurto, J. Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular Docking. J. Biomol. Struct. Dyn., 2019, 37(3), 584-610.
[http://dx.doi.org/10.1080/07391102.2018.1441072] [PMID: 29447615]
[67]
Thangapandian, S.; John, S.; Lee, K.W. Molecular dynamics simulation study explaining inhibitor selectivity in different class of histone deacetylases. J. Biomol. Struct. Dyn., 2012, 29(4), 677-698.
[http://dx.doi.org/10.1080/07391102.2012.10507409] [PMID: 22208272]
[68]
Ingham, O.J.; Paranal, R.M.; Smith, W.B.; Escobar, R.A.; Yueh, H.; Snyder, T.; Porco, J.A., Jr; Bradner, J.E.; Beeler, A.B. Development of a potent and selective HDAC8 inhibitor. ACS Med. Chem. Lett., 2016, 7(10), 929-932.
[http://dx.doi.org/10.1021/acsmedchemlett.6b00239] [PMID: 27774131]
[69]
Kashyap, K.; Kakkar, R. Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors. Comput. Biol. Med., 2020, 123, 103850.
[http://dx.doi.org/10.1016/j.compbiomed.2020.103850] [PMID: 32658783]
[70]
Liu, J.; Zhu, Y.; He, Y.; Zhu, H.; Gao, Y.; Li, Z.; Zhu, J.; Sun, X.; Fang, F.; Wen, H.; Li, W. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing. J. Biomol. Struct. Dyn., 2020, 38(2), 533-547.
[http://dx.doi.org/10.1080/07391102.2019.1590241] [PMID: 30938574]
[71]
Sirous, H.; Campiani, G.; Brogi, S.; Calderone, V.; Chemi, G. Computer-driven development of an in silico tool for finding selective histone deacetylase 1 inhibitors. Molecules, 2020, 25(8), 1952.
[http://dx.doi.org/10.3390/molecules25081952] [PMID: 32331470]
[72]
Sirous, H.; Campiani, G.; Calderone, V.; Brogi, S. Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. Comput. Biol. Med., 2021, 137, 104808.
[http://dx.doi.org/10.1016/j.compbiomed.2021.104808] [PMID: 34478925]
[73]
Ruzic, D.; Djokovic, N.; Nikolic, K. Fragment-based drug design of selective HDAC6 inhibitors. Methods Mol. Biol., 2021, 2266, 155-170.
[http://dx.doi.org/10.1007/978-1-0716-1209-5_9] [PMID: 33759126]
[74]
Ruzic, D.; Petkovic, M.; Agbaba, D.; Ganesan, A.; Nikolic, K. Combined ligand and fragment-based drug design of selective histone deacetylase – 6 inhibitors. Mol. Inform., 2019, 38(5), 1800083.
[http://dx.doi.org/10.1002/minf.201800083] [PMID: 30632697]
[75]
Balam, S.K.; Soora Harinath, J.; Krishnammagari, S.K.; Gajjala, R.R.; Polireddy, K.; Baki, V.B.; Gu, W.; Valasani, K.R.; Avula, V.K.R.; Vallela, S.; Zyryanov, G.V.; Pasupuleti, V.R.; Cirandur, S.R. Synthesis and anti-pancreatic cancer activity studies of novel 3-Amino-2-hydroxybenzofused 2-Phospha-γ-lactones. ACS Omega, 2021, 6(17), 11375-11388.
[http://dx.doi.org/10.1021/acsomega.1c00360] [PMID: 34056293]
[76]
Ortore, G.; Poli, G.; Martinelli, A.; Tuccinardi, T.; Rizzolio, F.; Caligiuri, I. From Anti-Infective Agents to Cancer Therapy: A Drug Repositioning Study Revealed a New Use for Nitrofuran Derivatives. Med. Chem., 2021, 18.
[77]
Yadav, V.; Banerjee, S.; Baidya, S.K.; Adhikari, N.; Jha, T. Applying comparative molecular modelling techniques on diverse hydroxamate-based HDAC2 inhibitors: An attempt to identify promising structural features for potent HDAC2 inhibition. SAR QSAR Environ. Res., 2022, 33(1), 1-22.
[http://dx.doi.org/10.1080/1062936X.2021.2013317] [PMID: 34979835]
[78]
Melge, A.R.; Parate, S.; Pavithran, K.; Koyakutty, M.; Mohan, C.G. Discovery of anticancer hybrid molecules by supervised machine learning models and in vitro validation in drug resistant chronic myeloid leukemia cells. J. Chem. Inf. Model., 2022, 62(4), 1126-1146.
[http://dx.doi.org/10.1021/acs.jcim.1c01554] [PMID: 35172577]
[79]
Hu, Z.; Lin, Q.; Liu, H.; Zhao, T.; Yang, B.; Tu, G. Molecular dynamics-guided receptor-dependent 4D-QSAR studies of HDACs inhibitors. Mol. Divers., 2022, 26(2), 757-768.
[http://dx.doi.org/10.1007/s11030-021-10181-y] [PMID: 33625673]
[80]
Kundu, R.; Banerjee, S.; Baidya, S.K.; Adhikari, N.; Jha, T. A quantitative structural analysis of AR-42 derivatives as HDAC1 inhibitors for the identification of promising structural contributors. SAR QSAR Environ. Res., 2022, 33(11), 861-883.
[http://dx.doi.org/10.1080/1062936X.2022.2145353] [PMID: 36412121]
[81]
Banerjee, S.; Baidya, S.K.; Adhikari, N.; Jha, T. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches. SAR QSAR Environ. Res., 2022, 33(12), 987-1011.
[http://dx.doi.org/10.1080/1062936X.2022.2155241] [PMID: 36533308]
[82]
Tinkov, O.V.; Grigorev, V.Y.; Grigoreva, L.D.; Osipov, V.N. HDAC1 PREDICTOR: A simple and transparent application for virtual screening of histone deacetylase 1 inhibitors. SAR QSAR Environ. Res., 2022, 33(12), 915-931.
[http://dx.doi.org/10.1080/1062936X.2022.2147996] [PMID: 36548122]
[83]
Ying, Y.; Taori, K.; Kim, H.; Hong, J.; Luesch, H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J. Am. Chem. Soc., 2008, 130(26), 8455-8459.
[http://dx.doi.org/10.1021/ja8013727] [PMID: 18507379]
[84]
Stoddard, S.V.; May, X.A.; Rivas, F.; Dodson, K.; Vijayan, S.; Adhika, S.; Parker, K.; Watkins, D.L. Design of potent panobinostat histone deacetylase inhibitor derivatives: Molecular considerations for enhanced isozyme selectivity between HDAC2 and HDAC8. Mol. Inform., 2019, 38(3), 1800080.
[http://dx.doi.org/10.1002/minf.201800080] [PMID: 30369061]
[85]
Al-Sanea, M.M.; Gotina, L.; Mohamed, M.F.A.; Grace Thomas Parambi, D.; Gomaa, H.A.M.; Mathew, B.; Youssif, B.G.M.; Alharbi, K.S.; Elsayed, Z.M.; Abdelgawad, M.A.; Eldehna, W.M. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety. Drug Des. Devel. Ther., 2020, 14, 497-508.
[http://dx.doi.org/10.2147/DDDT.S237957] [PMID: 32103894]
[86]
Ganai, S.A.; Abdullah, E.; Rashid, R.; Altaf, M. Combinatorial in silico strategy towards identifying potential hotspots during inhibition of structurally identical HDAC1 and HDAC2 enzymes for effective chemotherapy against neurological disorders. Front. Mol. Neurosci., 2017, 10, 357.
[http://dx.doi.org/10.3389/fnmol.2017.00357] [PMID: 29170627]
[87]
Martínez-Pacheco, H.; Espinosa-Raya, J.; Picazo, O.; Roldán-Roldán, G.; Viñas-Bravo, O.; Ramírez-Galicia, G. Design (Docking and QSAR Studies) and synthesis of histone deacetylase 2 (HDAC2) inhibitors series. Med. Chem. Res., 2018, 27(1), 206-223.
[http://dx.doi.org/10.1007/s00044-017-2051-2]
[88]
Pham-The, H.; Casañola-Martin, G.; Diéguez-Santana, K.; Nguyen-Hai, N.; Ngoc, N.T.; Vu-Duc, L.; Le-Thi-Thu, H. Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries. SAR QSAR Environ. Res., 2017, 28(3), 199-220.
[http://dx.doi.org/10.1080/1062936X.2017.1294198] [PMID: 28332438]
[89]
Zhou, H.; Wang, C.; Ye, J.; Chen, H.; Tao, R. Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors. Gene, 2017, 637, 63-71.
[http://dx.doi.org/10.1016/j.gene.2017.09.034] [PMID: 28939339]
[90]
Choubey, S.K.; Jeyakanthan, J. Molecular dynamics and quantum chemistry-based approaches to identify isoform selective HDAC2 inhibitor – a novel target to prevent Alzheimer’s disease. J. Recept. Signal Transduct. Res., 2018, 38(3), 266-278.
[http://dx.doi.org/10.1080/10799893.2018.1476541] [PMID: 29932788]
[91]
Anh, D.T.; Hai, P.T.; Huong, L.T.T.; Park, E.J.; Jun, H.W.; Kang, J.S.; Kwon, J.H.; Dung, D.T.M.; Anh, V.T.; Hue, V.T.M.; Han, S.B.; Nam, N.H. Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Bioorg. Chem., 2020, 101, 103988.
[http://dx.doi.org/10.1016/j.bioorg.2020.103988] [PMID: 32534346]
[92]
Mohamed, M.F.A.; Youssif, B.G.M.; Shaykoon, M.S.A.; Abdelrahman, M.H.; Elsadek, B.E.M.; Aboraia, A.S.; Abuo-Rahma, G.E.D.A. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors. Bioorg. Chem., 2019, 91, 103127.
[http://dx.doi.org/10.1016/j.bioorg.2019.103127] [PMID: 31374527]
[93]
Hieu, D.T.; Anh, D.T.; Hai, P.T.; Thuan, N.T.; Huong, L.T.T.; Park, E.J.; Young Ji, A.; Soon Kang, J.; Phuong Dung, P.T.; Han, S.B.; Nam, N.H. Quinazolin-4(3 H )-one-based hydroxamic acids: Design, synthesis and evaluation of histone deacetylase inhibitory effects and cytotoxicity. Chem. Biodivers., 2019, 16(4), e1800502.
[http://dx.doi.org/10.1002/cbdv.201800502] [PMID: 30653817]
[94]
Daniel, L.; Gotsbacher, M.P.; Richardson-Sanchez, T.; Tieu, W.; Codd, R. Exploring hydroxamic acid inhibitors of HDAC1 and HDAC2 using small molecule tools and molecular or homology modelling. Bioorg. Med. Chem. Lett., 2019, 29(18), 2581-2586.
[http://dx.doi.org/10.1016/j.bmcl.2019.08.002] [PMID: 31400937]
[95]
Xu, Z.; Yang, Y.; Mai, X.; Liu, B.; Xiong, Y.; Feng, L.; Liao, Y.; Zhang, Y.; Wang, H.; Ouyang, L.; Liu, S. Syntheses and biological evaluation of novel hydroxamic acid derivatives containing purine moiety as histone deacetylase inhibitors. Chem. Pharm. Bull., 2018, 66(4), 439-451.
[http://dx.doi.org/10.1248/cpb.c17-00997] [PMID: 29607910]
[96]
Ganai, S.A. Characterizing binding intensity and energetic features of histone deacetylase inhibitor pracinostat towards Class I HDAC isozymes through futuristic drug designing strategy; Silico Pharmacol, 2021, p. 9.
[97]
Ganai, S.A.; Srinivasan, P.; Rajamanikandan, S.; Shah, B.A.; Mohan, S.; Gani, M.; Padder, B.A.; Qadri, R.A.; Bhat, M.A.; Baba, Z.A.; Yatoo, M.A. Delineating binding potential, stability of Sulforaphane-N-acetyl-cysteine in the active site of histone deacetylase 2 and testing its cytotoxicity against distinct cancer lines through stringent molecular dynamics, DFT and cell-based assays. Chem. Biol. Drug Des., 2021, 98(3), 363-376.
[http://dx.doi.org/10.1111/cbdd.13854] [PMID: 33966346]
[98]
Dewaker, V.; Srivastava, P.N.; Verma, S.; Srivastava, A.K.; Prabhakar, Y.S. Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation. J. Biomol. Struct. Dyn., 2022, 40(24), 13432-13455.
[http://dx.doi.org/10.1080/07391102.2021.1989037] [PMID: 34662251]
[99]
Zhang, Y. Pseudobond ab initio QM/MM approach and its applications to enzyme reactions. Theor. Chem. Acc., 2006, 116(1-3), 43-50.
[http://dx.doi.org/10.1007/s00214-005-0008-x]
[100]
Micelli, C.; Rastelli, G. Histone deacetylases: Structural determinants of inhibitor selectivity. Drug Discov. Today, 2015, 20(6), 718-735.
[http://dx.doi.org/10.1016/j.drudis.2015.01.007] [PMID: 25687212]
[101]
Qin, H.T.; Li, H.Q.; Liu, F. Selective histone deacetylase small molecule inhibitors: Recent progress and perspectives. Expert Opin. Ther. Pat., 2017, 27(5), 621-636.
[http://dx.doi.org/10.1080/13543776.2017.1276565] [PMID: 28033734]
[102]
R, M.; P, H.A.; Mahadevan, V. HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells. J. Biomol. Struct. Dyn., 2018, 36(4), 938-955.
[http://dx.doi.org/10.1080/07391102.2017.1302820] [PMID: 28264628]
[103]
Amin, S.A.; Adhikari, N.; Jha, T. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies? Pharmacol. Res., 2017, 122, 8-19.
[http://dx.doi.org/10.1016/j.phrs.2017.05.002] [PMID: 28501516]
[104]
Amin, S.A.; Adhikari, N.; Jha, T. Diverse classes of HDAC8 inhibitors: In search of molecular fingerprints that regulate activity. Future Med. Chem., 2018, 10(13), 1589-1602.
[http://dx.doi.org/10.4155/fmc-2018-0005] [PMID: 29953251]
[105]
Shigematsu, N.; Ueda, H.; Takase, S.; Tanaka, H.; Yamamoto, K.; Tada, T. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J. Antibiot., 1994, 47(3), 311-314.
[http://dx.doi.org/10.7164/antibiotics.47.311] [PMID: 8175483]
[106]
Cole, K.E.; Dowling, D.P.; Boone, M.A.; Phillips, A.J.; Christianson, D.W. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J. Am. Chem. Soc., 2011, 133(32), 12474-12477.
[http://dx.doi.org/10.1021/ja205972n] [PMID: 21790156]
[107]
Hong, J.; Luesch, H. Largazole: From discovery to broad-spectrum therapy. Nat. Prod. Rep., 2012, 29(4), 449-456.
[http://dx.doi.org/10.1039/c2np00066k] [PMID: 22334030]
[108]
Bowers, A.A.; Greshock, T.J.; West, N.; Estiu, G.; Schreiber, S.L.; Wiest, O.; Williams, R.M.; Bradner, J.E. Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole. J. Am. Chem. Soc., 2009, 131(8), 2900-2905.
[http://dx.doi.org/10.1021/ja807772w] [PMID: 19193120]
[109]
Zeng, X.; Yin, B.; Hu, Z.; Liao, C.; Liu, J.; Li, S.; Li, Z.; Nicklaus, M.C.; Zhou, G.; Jiang, S. Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells. Org. Lett., 2010, 12(6), 1368-1371.
[http://dx.doi.org/10.1021/ol100308a] [PMID: 20184338]
[110]
Bhansali, P.; Hanigan, C.L.; Perera, L.; Casero, R.A., Jr; Tillekeratne, L.M.V. Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups. Eur. J. Med. Chem., 2014, 86, 528-541.
[http://dx.doi.org/10.1016/j.ejmech.2014.09.009] [PMID: 25203782]
[111]
Almaliti, J.; Al-Hamashi, A.A.; Negmeldin, A.T.; Hanigan, C.L.; Perera, L.; Pflum, M.K.H.; Casero, R.A., Jr; Tillekeratne, L.M.V. Largazole analogues embodying radical changes in the depsipeptide ring: Development of a more selective and highly potent analogue. J. Med. Chem., 2016, 59(23), 10642-10660.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01271] [PMID: 27809521]
[112]
Clausen, D.J.; Smith, W.B.; Haines, B.E.; Wiest, O.; Bradner, J.E.; Williams, R.M. Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole. Bioorg. Med. Chem., 2015, 23(15), 5061-5074.
[http://dx.doi.org/10.1016/j.bmc.2015.03.063] [PMID: 26054247]
[113]
Poli, G.; Di Fabio, R.; Ferrante, L.; Summa, V.; Botta, M.; Poli, G. Largazole analogues as histone deacetylase inhibitors and anticancer agents: An overview of Structure-activity relationships. ChemMedChem, 2017, 12(23), 1917-1926.
[http://dx.doi.org/10.1002/cmdc.201700563] [PMID: 29117473]
[114]
Dewaker, V.; Srivastava, P.N.; Verma, S.; Prabhakar, Y.S. Molecular dynamics study of HDAC8-largazole analogues co-crystals for designing potential anticancer compounds. J. Biomol. Struct. Dyn., 2020, 38(4), 1197-1213.
[http://dx.doi.org/10.1080/07391102.2019.1598497] [PMID: 30909817]
[115]
Dewaker, V.; Srivastava, A.K.; Arora, A.; Prabhakar, Y.S. Investigation of HDAC8-Ligands’ Intermolecular Forces through Molecular Dynamics Simulations: Profiling of Non-Bonding Energies to Design Potential Compounds as New Anti-Cancer Agents. J. Biomol. Struct. Dyn., 2020, 0, 1-26.
[PMID: 32578494]
[116]
Uba, A.İ.; Yelekçi̇, K. Exploration of the binding pocket of histone deacetylases: The design of potent and isoform-selective inhibitors. Turk. J. Biol., 2017, 41(6), 901-918.
[http://dx.doi.org/10.3906/biy-1701-26] [PMID: 30814855]
[117]
Maolanon, A.R.; Madsen, A.S.; Olsen, C.A. Innovative strategies for selective inhibition of histone deacetylases. Cell Chem. Biol., 2016, 23(7), 759-768.
[http://dx.doi.org/10.1016/j.chembiol.2016.06.011] [PMID: 27447046]
[118]
Krämer, O.H. HDAC2: A critical factor in health and disease. Trends Pharmacol. Sci., 2009, 30(12), 647-655.
[http://dx.doi.org/10.1016/j.tips.2009.09.007] [PMID: 19892411]
[119]
Gillette, T.G. HDAC inhibition in the heart. Circulation, 2021, 143(19), 1891-1893.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.121.054262] [PMID: 33970677]
[120]
Wilson, A.J.; Byun, D.S.; Popova, N.; Murray, L.B.; L’Italien, K.; Sowa, Y.; Arango, D.; Velcich, A.; Augenlicht, L.H.; Mariadason, J.M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem., 2006, 281(19), 13548-13558.
[http://dx.doi.org/10.1074/jbc.M510023200] [PMID: 16533812]
[121]
Zhu, P.; Martin, E.; Mengwasser, J.; Schlag, P.; Janssen, K.P.; Göttlicher, M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell, 2004, 5(5), 455-463.
[http://dx.doi.org/10.1016/S1535-6108(04)00114-X] [PMID: 15144953]
[122]
Huang, B.H.; Laban, M.; Leung, C.H-W.; Lee, L.; Lee, C.K.; Salto-Tellez, M.; Raju, G.C.; Hooi, S.C. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ., 2005, 12(4), 395-404.
[http://dx.doi.org/10.1038/sj.cdd.4401567] [PMID: 15665816]
[123]
Song, J.; Noh, J.H.; Lee, J.H.; Eun, J.W.; Ahn, Y.M.; Kim, S.Y.; Lee, S.H.; Park, W.S.; Yoo, N.J.; Lee, J.Y.; Nam, S.W. Increased expression of histone deacetylase 2 is found in human gastric cancer. Acta Pathol. Microbiol. Scand. Suppl., 2005, 113(4), 264-268.
[http://dx.doi.org/10.1111/j.1600-0463.2005.apm_04.x] [PMID: 15865607]
[124]
Schroeder, F.A.; Chonde, D.B.; Riley, M.M.; Moseley, C.K.; Granda, M.L.; Wilson, C.M.; Wagner, F.F.; Zhang, Y.L.; Gale, J.; Holson, E.B.; Haggarty, S.J.; Hooker, J.M. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors. Neurosci. Lett., 2013, 550, 119-124.
[http://dx.doi.org/10.1016/j.neulet.2013.06.016] [PMID: 23810801]
[125]
Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5(9), 769-784.
[http://dx.doi.org/10.1038/nrd2133] [PMID: 16955068]
[126]
Ouassi, M.; Giger, U.; Sielezneff, I.; Pirr, N.; Sastre, B.; Ouaissi, A. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J. Biomed. Biotechnol., 2011, 2011
[http://dx.doi.org/10.1155/2011/315939]
[127]
Kavianpour, P.; Gemmell, M.C.M.; Kahlert, J.U.; Rendina, L.M. Histone Deacetylase 2 (HDAC2) inhibitors containing boron. ChemBioChem, 2020, 21(19), 2786-2791.
[http://dx.doi.org/10.1002/cbic.202000131] [PMID: 32367603]
[128]
Methot, J.L.; Hoffman, D.M.; Witter, D.J.; Stanton, M.G.; Harrington, P.; Hamblett, C.; Siliphaivanh, P.; Wilson, K.; Hubbs, J.; Heidebrecht, R.; Kral, A.M.; Ozerova, N.; Fleming, J.C.; Wang, H.; Szewczak, A.A.; Middleton, R.E.; Hughes, B.; Cruz, J.C.; Haines, B.B.; Chenard, M.; Kenific, C.M.; Harsch, A.; Secrist, J.P.; Miller, T.A. Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor. ACS Med. Chem. Lett., 2014, 5(4), 340-345.
[http://dx.doi.org/10.1021/ml4004233] [PMID: 24900838]
[129]
Methot, J.L.; Hamblett, C.L.; Mampreian, D.M.; Jung, J.; Harsch, A.; Szewczak, A.A.; Dahlberg, W.K.; Middleton, R.E.; Hughes, B.; Fleming, J.C.; Wang, H.; Kral, A.M.; Ozerova, N.; Cruz, J.C.; Haines, B.; Chenard, M.; Kenific, C.M.; Secrist, J.P.; Miller, T.A. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett., 2008, 18(23), 6104-6109.
[http://dx.doi.org/10.1016/j.bmcl.2008.10.052] [PMID: 18951790]
[130]
Du, Y.; Tang, G.; Yuan, W. Suppression of HDAC2 by sodium butyrate alleviates apoptosis of kidney cells in db/db mice and HG‑induced NRK‑52E cells. Int. J. Mol. Med., 2020, 45(1), 210-222.
[PMID: 31746362]
[131]
Qi, Z.; Wang, C.; Jiang, J.; Wu, C. Novel C15 Triene Triazole, DA derivatives anti-HepG2, and as HDAC2 inhibitors: A synergy study. Int. J. Mol. Sci., 2018, 192018,

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy